<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: Hemodialysis patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> exhibit an excessive cardiovascular risk and regularly receive <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We tested whether antibodies to the platelet factor 4-<z:chebi fb="5" ids="28304">heparin</z:chebi> complex (<z:chebi fb="0" ids="30203">PF4</z:chebi>-H-AB) contribute to outcome </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN, SETTING, PARTICIPANTS, &amp; MEASUREMENTS: In 1255 hemodialysis patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, the German <z:mp ids='MP_0002055'>Diabetes</z:mp> Dialysis Study evaluated the effect of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (20 mg/d) versus placebo </plain></SENT>
<SENT sid="3" pm="."><plain>In a post hoc analysis, the association among <z:chebi fb="0" ids="30203">PF4</z:chebi>-H-ABs, biochemistry, and prespecified, centrally adjudicated end points (combined cardiovascular end point [CVE], <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality, <z:hpo ids='HP_0001699'>sudden death</z:hpo>, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo>) was investigated </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: During 4 years, 460 patients reached the CVE; 605 died, 159 of <z:hpo ids='HP_0001699'>sudden death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0001658'>Myocardial infarction</z:hpo> and <z:hpo ids='HP_0001297'>stroke</z:hpo> occurred in 199 and 97 patients, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Positive <z:chebi fb="0" ids="30203">PF4</z:chebi>-H-AB status was found in 231 (18.7%) of 1236 tested patients and was associated with lower albumin, higher C-reactive protein, and <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>In a multivariate model adjusted for demographics, comorbidities, and biochemistry, <z:chebi fb="0" ids="30203">PF4</z:chebi>-H-ABs were associated with <z:hpo ids='HP_0001699'>sudden death</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>No significant association between <z:chebi fb="0" ids="30203">PF4</z:chebi>-H-ABs and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo>, or the CVE was observed </plain></SENT>
<SENT sid="9" pm="."><plain>Detecting an interaction between <z:chebi fb="0" ids="15365">acetylsalicylic acid</z:chebi> and <z:chebi fb="0" ids="30203">PF4</z:chebi>-H-ABs regarding <z:hpo ids='HP_0001699'>sudden death</z:hpo> and mortality, we found that the association between <z:chebi fb="0" ids="30203">PF4</z:chebi>-H-ABs and outcomes was restricted to patients with <z:chebi fb="0" ids="15365">acetylsalicylic acid</z:chebi> use, most likely because of indication bias </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In hemodialysis patients who have type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and are treated with <z:chebi fb="0" ids="15365">acetylsalicylic acid</z:chebi>, <z:chebi fb="0" ids="30203">PF4</z:chebi>-H-ABs are associated with sudden and <z:hpo ids='HP_0000001'>all</z:hpo>-cause <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Further studies are needed to elucidate this association </plain></SENT>
</text></document>